What are the highlights
We are looking to hard to find alternatives to the establishment Republicans. I to want to find an alternative, but unvetted swamp salesmen are very dangerous. Maybe he is legitimate but maybe not. A close look is warranted.
The President of the United States is going to remain Donald Trump. End of story. Everything else is white noise.
I’m not seeing any connection between oxycontin and Vivek Ramaswamy. Can you provide proof of that connection?
As far as his investments in Alzheimer’s disease research, I guess I don’t see how that’s a bad thing.
Incorporating a business in Bermuda is a bad thing?
Sounds like you just hate wealthy people. Donald Trump is wealthy — do you hate him as well?
Not sure I’d take Kevin Paffrath’s opinion as gospel.
So ... besides ugly smears based on unfounded allegations, are there any concerns you have with his policies?
Meet Kevin never accomplished anything close to what Ramaswamy has done, oh wait he’s a YouTube star. Sorry. Only the weak minded, ignorant and those of low intelligence fall for Meet Kevin’s load of horse 💩.
Vifake 0bamaswamy
Vivek’s comment about everyone else on stage being bought and paid for, could be correct and was quite the shot across the bow.
No one else, including Bret was driving conversations deeper than typical GOP pablum.
Excuse me but I’d like to hear anyone step up and discuss ideas and issues with him.
After all, he’s just a kid standing there amidst our supposed best, seasoned, informed, conservative politicians.
I already know enough about some of the others on stage to know I don’t want to listen to any of their BS.
Let the Indian talk.
Soros Fellow.
This person is as worthless as a 3dollar bill.
https://www.fiercebiotech.com/biotech/why-axovant-s-315m-ipo-bonanza-should-scare-hell-out-of-you
Why Axovant’s $315M IPO bonanza should scare the hell out of you By John Carroll Jun 11, 2015 10:41am
Vivek Ramaswamy may not know anything about biotech and even less about treating Alzheimer’s, but he just provided a master class on the current state of public investing and executing IPOs in the field.
The bare bones of Ramaswamy’s new biotech venture, Axovant ($AXON), are much discussed these days. The former hedge fund manager grabbed an abandoned GlaxoSmithKline drug for Alzheimer’s for $5 million. He gathered a team together and without recruiting a single patient for a pivotal study of a marginal drug designed to treat symptoms of the disease, just raised $315 million in an upsized IPO that came in at the top of the range and promptly gyrated much higher today as investors bought in.
Axovant, with no track record, no experience and one questionable product, leaped onto the market worth much more than $1 billion.
Given the fact that GlaxoSmithKline had a chance to take a look at this drug in the clinic, and concluded that they couldn’t do better than selling it for lunch money, the IPO terms illustrate the kind of overnight riches a select few can find on Wall Street, provided you have the right kind of friends with money.
As Adam Feuerstein noted in a recent piece, two other hedge funds, RA Capital and Visium Asset Management, signaled an interest in buying up a bunch of these shares and were given a 90-day window to sell their shares, half the standard lock-up time.
None of this would be possible, of course, without the help of investors transfixed by the heady increase in the share prices of biotechs over the course of this bull market.
The fact that someone can make something of this size out of virtually nothing should be of concern to everyone in the industry. Magical thinking will take you just so far (remember the intoxicating dot-com days?). The argument that the market for biotech can stay stable rests on the belief that many of these new technologies in the clinic offer a fundamentally new and better way to treat many diseases. Something real. But when biotech mania takes over and perfectly legal schemes like this rain money, the pitfalls start to look like the Grand Canyon.